Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Two Basal Insulin Therapies for Patients With Type 1 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of type 1 diabetes for one year or more~* Age 18 years or older~* Body mass index (BMI) less than or equal to 35 kilograms per square meter (kg/m2)~* Have a hemoglobin A1c (HbA1c) 1.2 to 2.0 times the upper limit of the normal (ULN) reference range within 30 days prior to Visit 1 or collected and analyzed at a local laboratory at Visit 1~* As determined by the investigator, are capable and willing to do the following:~  * perform self monitoring of blood glucose (SMBG),~ * complete patient diaries as required for this protocol,~ * use the insulin injection device(s) according to the instructions provided,~ * are receptive to diabetes education,~ * comply with the required study visits.~Exclusion Criteria:~* Have taken any oral antihyperglycemic medications (OAMs) within 3 months prior to Visit 1.~* Have had more than one episode of severe hypoglycemia, as defined in the Abbreviations and Definitions section of the protocol, within 6 months prior to entry into the study~* Are pregnant or intend to become pregnant during the course of the study or are sexually active women of childbearing potential not actively practicing birth control by a method determined by the investigator to be medically acceptable or women who are breastfeeding~* Are receiving chronic (lasting longer than 14 consecutive days) systemic glucocorticoid therapy (excluding topical, intra-articular, intraocular, and inhaled preparations) or have received such therapy within the 4 weeks immediately preceding Visit 1.~* Have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Insulin Lispro Protamine Suspension (Type: EXPERIMENTAL): Insulin Lispro Protamine Suspension twice daily
- Detemir (Type: ACTIVE_COMPARATOR): Insulin Levemir (detemir) subcutaneous (SC) twice daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).